Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
about
Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu statusTrastuzumab-containing regimens for metastatic breast cancerTrastuzumab containing regimens for early breast cancerTrastuzumab containing regimens for early breast cancerTrastuzumab containing regimens for metastatic breast cancerAn activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancersIQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistanceRetroviral oncogenes: a historical primerCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsTrastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancerLong-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testingPolysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancerUpdate on HER-2 as a target for cancer therapy: herceptin in the clinical setting.Tyrosine kinase signalling in breast cancerNew targets for therapy in breast cancer: small molecule tyrosine kinase inhibitorsClinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC).CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasCardiac toxicity of trastuzumab in elderly patients with breast cancerClinical Development of the E75 Vaccine in Breast CancerFirst-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patientsMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerTumor-Derived Cell Lines as Molecular Models of Cancer PharmacogenomicsComplement in monoclonal antibody therapy of cancerTargeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicineRole of pertuzumab in the treatment of HER2-positive breast cancerTumor antigen-specific monoclonal antibodies and induction of T-cell immunityNovel immunotherapeutic strategies of gastric cancer treatmentProfile of neratinib and its potential in the treatment of breast cancerCombining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signalingPhase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumabRICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 InhibitorsNeratinib in HER-2-positive breast cancer: results to date and clinical usefulness
P2860
Q21195160-F95CABFB-794F-4524-B02B-7EE56FAD44A6Q24194019-F564C619-84CD-4B00-B4C8-073B6BBBA6B3Q24200192-911C3C37-8ECA-4433-B6A3-6AAD4101A858Q24244420-D20A9F2E-A83D-4351-94A4-D33F031DD9C7Q24244565-BED95D73-CCDC-4DC3-96A2-76C0B23F34CEQ24302462-F967F90D-53C5-4B62-AA82-CFDED81193B8Q24303562-C4B004EC-4B0D-48A0-9E3E-7766B611A164Q24309891-9D290E26-9BEB-480F-99AF-FEA0A4234D42Q24611142-028E1DF0-301D-4F3D-8FF6-721DE14A9A06Q24632064-A9F70CE6-A22A-48C5-AE76-7C4284D3C224Q24795614-8EC73EE2-9E97-4CE6-BBBA-E3958063F5D1Q24797752-95CF8E70-076F-4AF2-A520-F9D73052D294Q24797806-4B65132C-E67E-41A2-8BBD-AAF51D3713C8Q24801183-7EC8951E-A610-4B75-AB6A-A114453C4701Q24801924-0C38479A-CC84-40D0-A675-DE972FE82412Q24802908-07065C74-42BA-4992-94C3-27E92A32D497Q24806486-3B2D496D-7655-4613-B953-60A6D162E9BDQ24810552-87BCD13A-CAE7-486B-A614-98DE5CAA03D7Q24813543-943E7C8D-EDBA-4AB1-888E-9566716729E8Q24813788-FDA34E22-AB33-4484-86E2-A32BFB3FB5D1Q24814451-776F5D9B-B6CF-49CF-8D3C-9D463381BE38Q26740520-A56A1AE4-1922-4DA4-B5C8-824295DFF908Q26741182-0A7E29AF-BFB9-4AE9-9310-22AF8F457DC1Q26745440-286E0F05-1AEE-4CD2-BDA1-48E157BE7166Q26746081-C96EC1A0-08C6-496E-9596-4AA5538E84A1Q26752024-4FA5FA71-FC89-4D66-A16C-B1F8BE0E27CCQ26772969-838F914C-C88E-42EF-A958-362AAD44D96DQ26801410-55EEA69C-0121-4815-AB7D-4E0B65F44DB8Q26860800-47111070-1EA4-4BD9-B3BE-1C8F3A6411D2Q26865436-84E71BA2-56AC-48C0-B840-BE4A8086EE0CQ27002386-6ED3FBFC-CE46-4177-A16C-A9E5C952F2C1Q27009908-9A867CB6-0288-4347-9BD5-E46EEFD41D24Q27011232-8AF1343A-FBB2-4F9D-ABDC-D340E70C34BFQ27012540-781FCB7D-4337-4023-858D-450FF8EF8B22Q27824846-63D65156-1B64-49C9-9051-51AC12E137C1Q27851446-2D1C2138-D414-45F4-9F08-F103F1E713C4Q27851528-408103EE-BA64-4D6E-A5A1-9673290CF499Q27851864-A5F58B89-E0D4-4696-A7CC-ADFA03736496Q27853211-9B1B95B3-B8F1-4DB5-AC2D-F7F5E997FDE3Q28071303-1ED165F7-F5C1-403F-AF78-F6565FDAB6FA
P2860
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Multinational study of the eff ...... herapy for metastatic disease.
@en
type
label
Multinational study of the eff ...... herapy for metastatic disease.
@en
prefLabel
Multinational study of the eff ...... herapy for metastatic disease.
@en
P2093
P921
P1476
Multinational study of the eff ...... herapy for metastatic disease.
@en
P2093
D J Slamon
D Tripathy
G Lieberman
J M Wolter
L Fehrenbacher
M A Cobleigh
N J Robert
P304
P356
10.1200/JCO.1999.17.9.2639
P407
P577
1999-09-01T00:00:00Z